Vitex suspends trial for pathogen inactivation system
This article was originally published in Clinica
Executive Summary
VI Technologies (Vitex) has suspended a phase III study of its Inactine blood pathogen inactivation system, after one of the patients in the trial developed an immune response to cells treated with the technology. The company said that pending further evaluation with the US FDA, no additional patients would be recruited to the study. Inactine is designed to inactivate viruses, bacteria and parasites in red blood cells.